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Current studies on the influence of corticosteroids on the
feto-placental unit.
The prophylacticaltreatmentofrespiratoiy distress
syndrome with betamethasone is used successfully
inmanyclinics[2,6,19,20J21,27].Adisadvantage
of betamethasone administration is the regulär fall
of estrogen levels in maternal urine or plasma,
which may lead to difficulties in the evaluation of
the fetal condition in pregnancies at risk.
SIMMER et al. [24] and OHRLANDER and GENNSER
[18] have studied steroidgenesis in the fetoplacen-
tal unit following corticosteroid injection. They
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could show a decrease of total estrogens in 24-
hour-urine. OHRLANDER [18] and GENNSER [8]
where able to demonstrate a decrease of Cortisol in
maternal and fetal plasma and amniotic fluid
following betamethasone injection. ARAI [1]
reported a drop of estrogens in maternal and fetal
plasma after intramuscular injection of dexa-
methasone into the fetus in utero. TOWNSLEY [29]
showed a 19% reduction of estrogen excretion in
24-hour-urine following betamethasone injection
to the pregnant baboon. TOMBY RAJA [28] injected
betamethasone in order to reduce estrogen levels
äs a treatment to prevent premature labour.
In our investigations we wanted to examine the
influence of betamethasone on estrogen-bio-
synthesis in the piacenta and fetus. To our know-
ledge there is no study examining the changes of
steroid hormone levels in maternal plasma in short
intervals after betamethasone injection to the
mother. Furthermore we wanted to know wether
the changes of estrogen concentration in plasma
following betamethasone administration to the
mother could be of use äs a new dynamic functional
test of the piacenta and the fetus. It was also
planne d to test the steroidbiogenetic-function of
the piacenta after betamethasone suppression-of
the fetal pituitary-adrenal axis by DHA-S loading.
s
l Material and methods
We used Celestan Solubile made by BYK ESSEX,
l ml containing 5.3 mg. betamethasone-sodium-
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phosphate, representing 4 mg. betamethasone.
Maternal plasma concentrations of estrone
estradiol-17-beta (E2), estriol (E3), cortisol and
total estrogens in 24-hour-urine where determined
in normal and pathological third trimester preg-
nancies.
A total of 32 volunteers was examined and sub-
divided into VII groups.
Group I: Threepatientswith normaluncomplicated
pregnancies received 12 mg betamethasone intra-
muscularly on two successive days.
Group II: TwopatientssufferingfromEPH-gestosis
and one from placental insufficiency received
12 mg betamethasone intramuscularly on two
successive days.
Group III: Four patients with normal pregnancies
received 8 mg betamethasone intravenously.
Group IV: Three patients with normal pregnancies
received 8 mg. betamethasone and an additional
25 mg DHA-S intravenously three hours later.
Group V: Two patients with pathological preg-
nancies (placental insufficiency) received 8 mg
betamethasone. Three hours later they received
25 mg DHA-S intravenously.
Group VI: Four patients with normal pregnancies
received 8 mg betamethasone. 50 mgDHA-Swere
given intravenously 30 minutes later.
Group VII: Six patients with normal and six with
pathological pregnancies (placental insufficiency)
received 8 mg betamethasone and an additional
50 mg DHA-S intravenously three hours later.
Collection of 24-hour-urine for determination of
total estrogens was performe d the day before
injection and during the six following days.
Maternal venous blood for determination of E1?
E2, E3, äs well äs cortisol was drawn before injection
of betamethasone and at short intervals during the
first day of treatment (see figures for exact timing)
and one hour after the second injection on day 2
in groups I and II. One blood sample was drawn on
each of the six subsequent days at 9 a.m. The
plasma was separated by centrifugation at 3000 rpm
and stored frozen until used for the assay.
Radioimmunoassays of EJ, E2 and E3 were per-
formed with specific antibodies which were a gift
from Dr. GOEBEL, München and Dr. KÜNZIG,
Köln. The assay procedure was described previously
[25]. Different volumes of undiluted plasma were
extracted with 10 volumes of ether for determina-
tion of the unconjugated estrogen fractions. A
photometric method was employed to determine
the total urinary estrogens. Unconjugated cortisol
was determined by the method of MURPHY [16].
2 Results and discussion
The basal values of E l 9 E2, E3 in maternal plasma
were considerably higher in normal pregnancies
compared to pathological pregnancies (Fig. l, 2).
Following injection of betamethasone, plasma and
urinary concentrations of estrogensdecreasebecause
of diminished adrenocortical precursor availability
in the fetal and maternal compartment [23, 24].
The decrease of plasma-estrogens, cortisol and of
the urinary-estrogens is dose-dependent and reaches
a maximum after the second betamethasone in-
jection. A greater percentage of the total diminu-
ition in plasma estrogens is observed three hours
after the first betamethasone injection (Fig. l ,2,4).
The investigation of plasma estrogen changes
following betamethasone shows a great difference
between normal and pathological pregnancies. The
decrease of E2 three hours after intramuscular
injection of betamethasone was 69% of control
values in normal compared to 33% in pathological
cases. The drop of E3 was also more prominent in
normal pregnancies(63%) compared to complicated
cases (42%), (Fig. 1,2).
In normal pregnancies it took 3 days for estrogen
values to return to basal levels. In pathological
pregnancies 5 days were required before basal
values were attained. Thus pathological cases seem
to reach preinjection control estrogen values later
than normal pregnancies. Plasma E3 concentrations
need the longest time to return to basal values.
This could be caused by a longer suppression of
the fetal than of the maternal pituitary-adrenal
axis [24], Betamethasone may produce suppression
of 16X-hydroxlase in the fetal liver without in-
fluencing the placental aromatisation.
In one case of EPH-gestosis and intrauterine fetal
death, concentrations of E l 5 E2, and E3 showed
little change following betamethasone in contrast
to normal control cases. A more pronounced
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' Fig. 1. Plasma estradiol-17-0 after betamethasone administration in normal and pathological pregnancies. Mean values.
Normal: base values = 20-40-12 ng/ml, SD = 14.42; 3 hrs. after = 6.8-11-4, SD = 3.52. Pathological: base values
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Fig. 2. Plasma estriol after betamethasone administration in normal and pathological pregnancies. Mean values. Normal:
base values = 12-16-6.8, SD = 4.61; 3 hrs. after = 2.5-7-2.2, SD = 2.68. Pathological: base values = 3-5.2-2.3
SD = 1.51; 3 hrs. after = 2.2-3.2-0.70, SD = 1.25.
decrease of plasma estrogens in cases of in- In contrast to the studies of' HRLANDER [18],
trauterine fetal death should be,expected if the who described a return to basal cortisol values
matemal adrenal cortex is suppressed to a major after three weeks, we found that a nonnaUsation
extent
- of cortisol values has already occurred three days
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Fig. 3. Total estrogens in 24-h-urine after betamethasone administration. Mean values. Normal: base values = 18-27.9-
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Fig. 4. Estrone, estradiol-17-0 and estriol in plasma after iv. injection of 8 mg betamethasone. Mean values of 4 normal
pregnancies. For El base vaiues = 24-16-30-17, SD = 6.55; 3 hrs. after = 21-16.5-16-10.4, SD = 4.34. For E2
base values = 31-37.5-30-54, SD = 11.09; 3 hrs. after = 20-25-8.5-6.2, SD = 9.03. For E3 base values = 33-17.5-
18-34, SD = 9.10; 3 hrs. after = 4.3-1.6-6-7.2, SD = 2.42.
after the second betamethasone application. It is
to be stressed however that the cortisol levels in
our patients were mostly within normal limits.
The concentrations of DHA in maternal plasma
and urine show only a small change following
betamethasone application in normal and patho-
logical pregnancies [17].
Since the suppression of the maternal adrenal
cortex following betamethasone is about the same
in normal and pathological pregnancies, one could
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draw the conclusion that differences in estrogen
decreases are mostly due to the difference in
suppression of estrogen precursor-biosynthesis
between the normal fetus and the fetus at risk.
Changes of plasma estrogens following beta-
methasone application correspond well with
changes of urinary estrogens (Fig. 3). The maximal
mean decrease of urinary estrogens was 76% in
normal pregnancies. It was reached the first day
after the second betamethasone application. At
the same time the maximal drop for the lower
control values of pathological pregnancies was
only 50% of basal values. The return to basal
values was not reached within four days after the
second betamethasone injection in both groups.
It has been reported, that the return to basal values
is reached in 2—3 weeks [5, 20] or after 5—6 days
421,22].
Maternal plasma concentrations of estrone (E^
did not show specific changes during the first days
following betamethasone injection.
According to the results from the patients of group
IV, V and VI plasma E2 and E3 show more
pronounced decreases in normal pregnancies than
in pathological pregnancies. The E2 and E3 increase
occurring 30 minutes after DHA-S injection is also
higher in normal pregnancies (Fig. 5,6).
Intravenous injection of 50 mg DHA-S immediately
after intravenous betamethasone injection causes a
smaller increase of plasma E3 (since the suppression
of the fetal pituitary-adrenal axis is still minimal at
this time) than a smaller ;dose of DHA-S (25 mg)
administered three hours later (Fig. 7).
A hypothetical explanation is that endogenous
estrogen precursors and exogenous DHA-S compete
for aromatisation in the placent [10,13, 30].
The increase of plasma E3 (89%) following DHA-S
injection in patients of group IV is quite similar to
that in the cases examined by STRECKER and
LAURITZEN [25]. BUSTER [3] did not find an
increase of plasma E3 following DHA-S injection.
The increase of E3 after betamethasone Inhibition
could be explained by an activation of the „phenolic
pathway" (16-alfa-hydroxylation in the maternal
liver)[7,22j.
The different patterns of plasma concentrations
for £2, E3 and urinary estrogens following beta-
methasone and DHA-S injection in normal and
pathological pregnancies encouraged us to apply
this idea to a new modified dynamic test of feto-
placental function: „A betamethasone suppression-
PHA-S Stimulation Test". We think that this test
will give us more and new Information about fetal
and placental compartments in normal and patho-
logical pregnancies.
The influence of betamethasone on the feto-
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Fig. 5. Plasma estradiol-17-0 after betamethasone administration and additional injection of 25 mg DHA^S iv. Mean
iTs^Tln ™ <nUeo *012ρΛ^~9·6' SD = h28; 3 hrS' **" betametha*one = 6.5-2-12.4, SD = 5.2; 30' after
- ntS ",2Vn ~
 fi ' ?ΛΤ 2:**·Ρ*'*°*>&** (dotted line): base values = 16 8.5, SD = 5.30; 3 hrs. after betamethasone
- 9.5-5.5, SD = 2.82; 30' after DHA-S = 16-14.5, SD = 1.06.
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Fig. 6. Plasma estriol after betamethasone administration and additional injection of 25 mg DHA-S i.v. Mean values.
Normal: base values = 12-11.6-9.6, SD = 1.28; 3 hrs. after betamethasone = 5.8 3.4-4.6, SD = 1.2; 30' after DHA-S
= 10-9-6.4, SD = l.SS.Pathological (dotted line): base values = 5-3.6, SD = 0.98; 3 hrs. after betamethasone = 4.1-4,
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Fig. 7. Plasma estriol after betamethasone administration and subsequent injection of 25 or 50 mg DHA-S in normal
pregnancies. Mean values. For 25 mg DHA-S the individuel values and SD are identical with values of Fig. 6. For 50 mg
DHA-S: base values = 8.4-6-6.4-7.3, SD = 1.06; 30' after betamethasone = 7.6-4.2-4.2-7.6, SD = 1.96; 30' after
DHA-S = 7.5-2.6-5.6-3.2, SD = 2.3.
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Stimulation: /Inhibition: ,decrease: t .
Fig. 8. Schematic outline of the inhibiting effect of betamethasone on steroid production in maternal and fetal adrenals
s consequence of ACTH-suppression in the pituitary.
3 Basal theoretical knowledge concerning the test
Investigations of ophorectomized patients have
show that there is a minimal basal DHA secretion of
the adrenal cortex even after complete suppression
of ACTH. Also, it is well known that there is no
gonadal DHA production in the fetus. OHRLANDER
[18] could show there is minimal estriol excretion
in maternal urine (aproximately 2 mg) even after
complete suppression of ACTH. These results show
the existence of a basal adrenal cortex secretion of
estrogen precursors which is independent of hypo-
thalamic-pituitary Stimulation. One could say that
after suppression of the pituitary-adrenal cortex
axis by betamethasone, the determination of plasma
estrogens gives Information about the basal adrenal
secretion of estrogen precursors and the extent of
adrenal cortical suppression.
CHALLIS [4] has examined plasma concentrations
of androstenedione, testosterone, estrogens and
cortisol after betamethasone application to rhesus
monkeys. He found a more pronounced suppression
of estrogens than androgens. The androgens
remained at a constant level after an initial drop.
The decrease of estrogens was continual, indicating
that it was caused by a suppression of the fetal
adrenal cortex.
SIMMER demonstrated [23, 24] that the decrease
of €χ9 estrogen precursors following corticosteroid
application was more intense in the umbilical vein
than in maternal plasma.
We believe that the dynamic determination of
maternal plasma estrogens after betamethasone
application represents a test for the suppression
of the pituitary-adrenal cortex axis.
The following reasons are listed in support of this
contention:
1. The extent of the plasma estrogen decrease
following betamethasone application shows
predominantiy the fetal portion of the pool of
estrogen-precursors. Maternal precursors show
little change.
2. The basal estrogen level that remains constant
over a period of time after betamethasone
suppression shows preponderately the maternal
portion of the pool of estrogen precursors.
3. The extent of the estrogen-fall represents a
measure of the fetal pituitary-adrenal suppression
and of the ability of the adrenal cortex to
respond to factors acting on the feed back
mechanisms. This may be important for the
adaptation to situations of stress in utero.
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4. After maximal suppression of the fetal estrogen
precursors, conditions of an "in vivo" isolation
of the placenta are created.
In this way it should be possible to evaluate separa-
tely e.g. the aromatisation rate of the placenta
after DHA-S loading without interference from the
fetal or maternal side.
The response of the adrenal cortex to pituitary
ACTH depends on the intensity and duration of
this Stimulation. The adrenal cortex of a normal
fetus reacts with an imme diäte and adequate
secretion of corticosteroids. ISHERWOOD and
OAKEY [9] could demonstrate an increased pro-
duction of androgens "in vitro" following ACTH-
stimulation. Direct injection of ACTH and HCG
into the fetus showed significant rises of maternal
estrogens via an increase of fetal estrogen precursors
[1,12,26].
Animal investigations have shown an increased
secretion of ACTH in fetus suffering from chronic
or acute hypoxia. There was no rise of plasma-
cortisol levels found in fetuses with chronic
hypoxia [31].
The estrogen response pattern following beta-
methasone application changes with the condition
of the fetus. A healthy, normal fetus reacts with a
more intense decrease of estrogens than a fetus at
risk, and the retum to values before injection is
more rapid.
In normal pregnancies the decline of E3 three
hours after intravenous injection of 8 mg beta-
methasone exceeds 50% of preinjection values.
This decrease showed good correlations to clinical
Undings, erg. the cardiotocogram and human
placental lactogen (HPL).
HPL levels are not influenced by corticosteroid
application to themother[19,20,32].OHRLANDE R
[18] could show a direct correlation between basal
estriol-excretion in the 24-h-urine and its decrease
after betamethasone injection.
In pathological pregnancies the decline of the
primarily low estrogen levels is less distinct and the
return to basal values is slower.
The most important criteria for the Interpretation
of the estrogen curves following betamethasone
suppression seem tobe the extension of the plateau
together with the amplitude of the curve and the
time required for preinjection control values to be
reached.
With an additional application of 50 mg DHA-S
three hours after betamethasone injection to the
mother and determination of maternal plasma
estrogens in short intervals there might be the
possibility of a new more sophisticated functional
method of determining placental function: "An
Inhibition test of the fetal pituitary-adrenal cortex
axis combined with a loading-test of the placenta."
This test could evaluate the condition of the fetus
by determination of E3 after betamethasone
application to the mother and could also clarify
the reserve capacity of the placenta following
DHA-S loading, in a state of maximal suppression
of the endogenous estrogen-precursors by deter-
mination of E2 (Fig. 9).
There are numerous reports about the theory and
the clinical value of the DHA-S loading-test in
plasma [10,11,13,14,15, 25, 30].
The criteria of normality for this part of the com-
bined test mentioned above agree with those.
reported by STRECKER and LAURITZEN [25].
In this way an improvement of the DHA-S loading
test may be possible since the fetal and to a
smaller extent the maternal estrogen precursors are
excluded.
The following conclusions can be drawn from our
investigations
l.The changes of plasma and urinary estrogen
levels depend on the dose of betamethasone and
on the way of application.
2. The maximal decrease of maternal E2 and E3 is
reached three hours after injection. The return
to preinjection values takes more than 4-5
days.
3. The decline of estrogens following beta-
methasone injection to the mother is caused by
suppression of adrenocortical estrogen-precursors
mainly derived from the fetus.
4. The changes of maternal plasma estrogens after
betamethasone and subsequent DHA-S loading
offer new possibilities for testingthe fetoplacental
unit.
J. Perinat. Med. 5 (1977)







Fig. 9. "A betamethasone suppression DHA-S-loading test". Suppression of plasma estriol after betamethasone
administration äs index of fetal condition and subsequent evaluation of placental function by DHA-S loading. A hypo-
thesis for a new combined test of fetus and placen ta demonstrated in 6 normal and 6 pathological (placental insufficiency)
cases. Mean and SD values. For E3 base and 3 hrs. after betamethasone values p < 0,0025 (Student test).
Summary
The effect of betamethasone on the estrogen-biosynthesis
in placenta and fetus was tested. It was ashed whether the
changes of estrogen concentration in plasma following
betamethasone administration to the mother could be of
use äs a new dynamic functional test of the placenta and
the fetus. It was also planned to test the placental steroido-
genetic function after betamethason suppression of the
fetal pituitary-adrenal axis, by DHA-S loading.
Maternal plasma concentrations of estrone (Ej), estradiol
17-0 (E2), estriol (E3), cortisol and total estrogens in
24-h-urine where determined in normal and pathological
third trimester pregnancies.
A total of 32 patients was examined und subdivided into
VII groups.Group 1,11 andlllreceived 12 mg betamethasone
im. or 8 mg iv. Group IV, V,VI, VII received betamethasone
and also 25 or 50 mg DHA-S iv.
Maternal venous blood for determination of Ej, E2 and
E3 äs well äs cortisol was drawn before injection of
betamethasone and at short intervals during the first day
of treatment (see figures for exact timing) and one hour
after the second injection on day II in the cases of group I
and II. One blood sample was drawn on each of the six
subsequent day s at 9 a.m.
E!, E2 and E3 were determined by radioimmunoassay.
A photometric method was employed to determine the
total urinary estrogens.
Unconjugated cortisol was determined by the method of
MURPHY.
The basal values of E1? E2, E3 in mafernal plasma where
considerably higher in normal pregnancies than in patho-
logical pregnancies (Fig. l, 2, 3, 4).
The decrease of plasma-estrogens, cortisol and of the
urinary-estrogens is dose dependent and reaches a mäxi-
mum on the second betamethasone injection (Fig. l, 2, 3).
Plasma estrogen changes following betamethasone show a
great difference between normal and pathological preg-
nancies. The decrease of E2 three hours after intramuscular
injection of betamethasone was 69% in normal compaied
to 33% in pathological cases.
The drop of E3 was also more prominent in normal preg-
nancies (63%) than in complicated cases (42%) (Fig. l
and 2).
Estrogen values of normal pregnancies returned to basal
values three days after injection. In pathological preg-
nancies 5 days elapsed before values were normal again.
In patients of group IV, V and VI the increases of plasma
E2 and E3 occurring 30 minutes after DHA^S injection
are also higher in normal that in pathological pregnancies
(Fig. 5, 6).
The different patterns of plasma concentrations of E2, E3
and urinary estrogens following betamethasone and DHA-S
injection in normal and pathological pregnancies encour-
aged us to apply this idea to a.new modified dynamic test
of feto-placental function: "AJbetamethasone suppression
DHA-S-loading Test".
The estrogen response pattern following betamethasone
application changes with the condition of the fetus. A
healthy, normal fetus reacts with a more intense decrease
of estrogens than a fetus at risk and the return to values
before injection is more rapid.
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In cases of a "normal response" the decline of E3 three
hours after intravenous injection of 8 mg betamethasone
exceeds 50% of preinjection values.
In pathological pregnancies the decline of the primarily
low estiogen levels is less distinct and the return to basal
values is slower.
With an additional application of 50 mg DHA-S three
hours after betamethasone injection to the mother and
determination of maternal plasma estrogens in short inter-
vals there might be the possibility of a new functional
method determining placental function: "An Inhibition
test of the fetal pituitary-adrenal axis combined with a
loading-test of the placenta.".
This test could evaluate the condition of the fetus by
determination of £3 after betamethasone application to
the mother and could also clarify the reserve capacity of
the placenta following DHA-S loading in a state of maxi-
mal suppression of the endogenous estrogen-precursors
by determination of E2 (Fig. 9).
The following conclusions can be drawn from our in-
vestigations:
1. The changes of plasma and urinary estrogens depend on
the dose of betamethasone and on the way of application.
2. The maximal decrease of maternal E2 and £3 is reached
three hours after injection. The return to preinjection
values takes more than 4-5 days.
3. The decline of estrogens following betamethasone in-
jection to the mother is causes by suppression of
adrenocortical estrogen-precursors mainly derived from
the fetus.
4. The changes of maternal plasma estrogens after beta-
methasone and subsequent DHA-S loading offer new
possibilities for testing the fetoplacental unit.
Keywords: DHA-S-loading test, dynamic functional test, feto-placental unit, placental insufficiency
Zusammenfassung
Der Einfluß von Betamethason auf die fetoplazentare
Einheit.
In unserer Studie soll der Einfluß von Betamethason auf
die Oestrogen-Biosynthese in Fet und Plazenta untersucht
werden. Weiterhin wollen wir herausfinden, ob Verände-
rungen der mütterlichen Östrogenkonzentration im Plasma
nach Verabreichung von Betamethason an die Mutter als
ein neuer, dynamischer funktioneller Test für Fet und
Plazenta herangezogen werden können. Ebenso war vor-
gesehen, die Plazenta durch DHA-S- Belastung zu testen,
nachdem, die fetale Hypophysen-Nebennierenrindenachse
durch Betamethason supprimiert wurde.
Die mütterlichen Plasma-Spiegel von Östron (Ej), Östra-
diol 17-0 (E2), Östriol (E3), Cortisol und die Gesamt-
Östrogene im 24-h-Urin wurden bei normalen und patho-
logischen Schwangerschaften im 3. Trimenon bestimmt.
Die Gesamtzahl von 32 Patientinnen wurde in 7 Gruppen
unterteilt.
Die Gruppen I, II und III erhielten 12 mg Betamethason
i.m. oder 8 mg i.v. Die Gruppen IV, V, VI, VII erhielten
Betamethason und zusätzlich 25 oder 50 mg DHA-S i.v.
Mütterliches Venenblut für die Bestimmungen von EI, E2,
E3 und Cortisol wurden vor der Injektion von Betametha-
son und in kurzen Zeitabständen während des 1. Behand-
lungstages (genaue Zeitabstände bitte den Abbildungen
entnehmen) sowie l Stunde nach der 2. Injektion am Tag
II in der Gruppe I und II abgenommen. Eine Probe wurde
jeweils an den 6 folgenden Tagen um 9.00 h entnommen.
E!, E2 und E3 wurden radioimmunologisch bestimmt, die
Gesamtöstrogene im Urin wurden photometrisch gemessen.
Freies Cortisol wurde nach der Methode von Murphy be-
stimmt.
Die Basalwerte von EI, E2 und E3 im mütterlichen Plasma
waren bei normalen Schwangerschaften signifikant höher,
als bei pathologischen Fällen (Abb. l, 2, 3,4).
Der Abfall der Plasma-Östrogene, Cortisol und der Ge-
samtöstrogene im Urin ist dosisabhängig und erreicht
ein Maximum nach der 2. Be tarne thason-Injektion
(Abb. 1,2,3).
Die Untersuchungen der Verlaufskurven für die Plasma-
Östrogene nach Betamethason zeigen einen großen Unter-
schied zwischen normalen und pathologischen Schwan-
gerschaften. Der Abfall von Östradiol drei Stunden nach
intramuskulärer Injektion von Betamethason betrug 69%
bei normalen, im Vergleich zu 33% bei pathologischen
Fällen. Der Abfall von £3 war bei normalen Schwanger-
schaften ebenfalls ausgeprägter als bei komplizierten
Fällen (63 gegen 42%) (Abb. l und 2).
Die Östrogenwerte erreichten bei normalen Schwanger-
schaften den Basalwert nicht vor 3 Tagen nach der In-
jektion im Gegensatz zu 5 Tagen bei pathologischen
Fällen.
Gemäß den Ergebnissen, die wir bei den Patienten-
Gruppen IV, V und VI erhalten haben, sind die Anstiege
von E2 und E3 30 Minuten nach DHA-S-Injektion bei
normalen Schwangerschaften höher als bei pathologischen
Fällen (Abb. 5 und 6).
Die unterschiedlichen Kurvenverläufe von E2, £3 und der
Urin-Östrogene nach Betamethason-Injektionen bei nor-
malen und pathologischen Schwangerschaften veranlaßten
uns, einen neuartigen, modifizierten, dynamischen Test
für die Beurteilung der fetoplazentaren Funktion vorzu-
schlagen: „den Betamethason-Suppressions-DHA-S-
Belastungstest!"
Das Antwortmuster der Östrogene nach Betamethason-
Verabreichung verändert sich mit dem Zustand des Feten.
Ein gesunder, normaler Fet reagiert mit einem stärkeren
Abfall der Östrogene, als ein vorgeschädigter Fet und das
Wiederaufsteigen zu den Basalwerten geschieht schneller.
Bei Fällen mit einer normalen Antwort übersteigt der Ab-
fall von £3 -3 Stunden nach intravenöser Injektion von
8 mg Betamethason - 50% des Basalwertes.
Bei pathologischen Schwangerschaften ist der Abfall der
schon primär niedrigen Östrogenwerte weniger ausgeprägt
und die Rückkehr zu den Basalwerten langsamer. Mit zu-
sätzlicher Verabreichung von 50 mg DHA-S, 3 Std. nach
Be tarne thasongabe an die Mutter und Bestimmung der
mütterlichen Plasma-Östrogene in kurzen Zeitabständen,
könnte sich ein Weg zu einem neuen, funktioneilen Test
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für die Beurteilung der Plazenta-Funktion ergeben: Ein
Hemmungstest der fetalen Hypophysen-Nebennieren-
rindenachse kombiniert mit einem Belastungstest für die
Plazenta. Dieser Test könnte durch die E3-Bestimmung
nach Betamethason-Verabreichung an die Mutter Aus-
kunft über den Zustand des Feten geben und zudem die
Reserve-Kapazität der Plazenta nach DHA-S-Belastung
durch die Bestimmung von E2 beurteilen. In diesem Zu-
stand ist nämlich die Produktion der endogenen Östrogen-
Präkursoren maximal supprimiert (Abb. 9).
Folgende Schlußfolgerungen können aus unseren Unter-
suchungen gezogen werden:
l.Die Veränderungen der Plasma- und Urin-Östrogene
sind abhängig von der Betarnethason-Dosis und der
Verabreichungsform.
Schlüsselwörter: DHA-S-Belastungstest, dynamischer Plazentafunktionstest, fetoplazentare Einheit, Plazentarinsuffizienz.
2. Der maximale Abfall von mütterlichem E2 und E3
wird drei Stunden.nach der Injektion erreicht. Die
Rückkehr zu Basalwerten, erfolgt erst nach vier bis
fünf Tagen.
3. Der Abfall der Östrogene nach Betamethason-Injektion
an die Mutter entsteht hauptsächlich durch die Suppres-
sion der adreno-corticalen Östrogenpräkursoren, die
vom Feten stammen.
4. Die Veränderungen der mütterlichen Plasma-Östrogene
nach Betamethason und nachfolgender DHA-S-Belastung
zeigen neue Wege auf, den Zustand der feto-plazentaren
Einheit beurteilen zu können.
Resume
v
 Influence de la betamethasone sur Tunke foeto'placentaire
Dans le present article nous avons examine Finfluence de
betamethasone sur la biosynthese des oestrogenes dans le
placenta et le foetus. De plus, nous avons cherche a savoir
si des modifications des concentrations dOestrogenes
dans le plasma apres administration de betamethasone a
la mere pourraient etre utilisees comme un nouveau test
fonctionnel et dynamique du placenta et du foetus. Nous
avons essaye aussi de tester par Charge DHA-S la fonction
steroidobiogenetique du placenta apres la suppression de
Taxe hypophiso-adrenocortical par betamethasone.
A cet effet, nous avons determine les concentrations plas-
ma tiques maternelles de l'oestrone (OEj), de l'oestradiol
(OE2>, de l'oestriol (OE3), du Cortisol et ceUes des
oestrogenes de l'urine de 24 heures au troisieme trimestre
degrossesses normales et pathologiques. Les 32 parturientes
examinees ont ete reparties en VII groupes. Les groupes
I, II et III ont re$u 12 mg ou 8 mg de betamethasone i.m
Les groupes IV, V, VI et VII ont regu la betamethasene et
aussi 25 mg ou 50 mg de DHA-S i.v.
L'OEj,
 2 et 3 ainsi que le cortisol ont ete determi-
nes dans le sang veineux avant l'injection de betamethasone
et a courts intervalles pendant la premiere journee du
traitement (cf. les graphiques pour les temps precis) et
une heure apres la seconde injection au deuxieme jour
dans les cas des groupes I et II.
Un prelevement a ete effectue a 9 h. du matin chacun des
six jours suivants. LOEi, 1OE2 et 1OE3 plasmiques ont
ete definis par la methode radioimmunologique et les
oestrogenes totaux urinaires par methode photometrique.
Le cortisol non-conjugue a ete determine par la methode
de MURPHY.
Les concentrations d'OElf dOE2 et d'OE3 en plasma
maternel avant l'injection de betamethasone ont ete
considerablement plus elevees dans les grossesses normales
que dans ceUes pathologiques (fig. l, 2, 3,4).
La baisse des oestrogenes plasmatiques, du cortisol et des
oestrogenes urinaires depend de la (lose et atteint un
maximum apres la.seconde injection de betamethasone
(fig. l, 2, 3). Les investigations des changements des
oestrogenes plasmatiques apres betamethasone montrent
une grande difference entre les grossesses normales et
pathologiques. La baisse d'OE^ trois heures apres l'injec-
tion intramusculaire de betamethasone a atteint 69%
dans les grossesses normales et seulement 33% dans les
grossesses pathologiques' La baisse dOE3 a ete egalement
plus importante dans les cas normaux (63%) que dans les
cas compliques (42%) (fig. l et 2).
Les valeurs des oestrogenes en grossesse normale ont
retrouve leur niveau de depart trois jours seulement apres
l'injection et meme 5 jours pour les grpsses pathologiques.
Selon les resultats des patientes des groupes IV, V et VI,
les hausses dOE2 et dOE3 plasmiques 30 minutes apres
l'injection de DHA-S sont plus grandes en grossesse
normale qu'en grossesse pathologique. (fig. 5 et 6).
La difference des courbes des concentrations plasmiques
d'OE2, d'OE3 et des oestrogenes urinaires apres l'injection
de betamethasone et de DHA-S entre les grossesses normales
et pathologiques nous a incites a„appliquer cette idee
comme un nouveau test dynamique de la fonction foeto-
placentaiie: «Un test d'inhibition par betamethasone et de
Stimulation par DHA-S».
La reaction des oestrogenes apres l'injection de betametha-
sone varie selon la condition du foetus. Un foetus normal
et sain reagit par une baisse plus forte des oestrogenes
qu'un foetus «a risque» et le retour aux valeurs de base
(c.a.d. precedant l'injection) est plus rapide.
Dans les cas d'une «reaction normale», la baisse d'OE3
trois heures apres l'injection intraveineuse de 8 mg de
betamethasone depasse 50% des valeurs initiales. Dans les
cas des grossesses pathologiques la baisse des valeurs
initialement basses des oestrogenes est moins prononcee
et le retour aux valeurs de base est plus lent.
L'injection supplementaire de 50 mg de DHA-S trois
heures apres l'injection de betamethasone a la mere et la
determination des oestrogenes plasmatiques maternels a
courts intervalles pourrait nous donner la possibilite
d'appliquer une nouvelle methode pour definir la fonction
placentaire: «Un test d'inhibition de Taxe hypophiso-
adrenocortical combine avec un loading-test» du placenta.
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Ce test pourrait permettre d'evaluer la condition du foetus
en determinant 1OE3 apres l'injection de betamethasone
ä la mere ainsi que la capacite de reserve placentaiie apres
Padministration de DHA-S au moment de la suppression
maximale des precurseurs endogenes des oestrogenes par
determination dOE2 (fig. 9). Les resultats obtenus nous
ont permis de tirer les conclusions suivantes:
1. Les vaiiations des oestrogenes plasmatiques et urinaiies
dependent de la dose et de la maniere d'application de
la betamethasone.
2. La baisse maximale de
 2 et de 1OE3 materneis
plasmatiques est obtenue trois heures apres l'injection.
Le retour aux valeurs initiales dure plus de 4-5 jours.
3. La baisse des oestrogenes suivant l'injection de beta-
methasone resulte de la suppression des precurseurs
adrenocorticals des oestrogenes, principalement
produits par le foetus.
4. Les variations des oestrogenes plasmatiques materneis
apres l'injection de betamethasone et de DHA-S nous
offre des nouvelles perspectives pour tester l'unite
foeto-placentaire.
Mots-cles: DHA-S-«loading-test», insufficance placentaire, test fonctionnel dynamique, unite foeto-placentaire.
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